Abbott Laboratories (BVL:ABT)

Abbott Laboratories Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	13,402	5,723	6,933	7,071
Depreciation & Amortization	3,218	3,243	3,267	3,538
Loss (Gain) From Sale of Assets	482	126	215	55
Stock-Based Compensation	673	644	685	640
Change in Accounts Receivable	-691	-356	-68	-383
Change in Inventory	-58	-232	-1,413	-456
Change in Accounts Payable	356	-760	420	1,288
Change in Income Taxes	-8,028	-585	-383	-908
Change in Other Net Operating Assets	-796	-542	-75	-312
Operating Cash Flow	8,558	7,261	9,581	10,533
Operating Cash Flow Growth	17.86%	-24.21%	-9.04%	33.31%
Capital Expenditures	-2,207	-2,202	-1,777	-1,885
Cash Acquisitions	-	-877	-	-187
Divestitures	1	40	48	134
Investment in Securities	-141	-116	-33	-96
Other Investing Activities	9	22	22	26
Investing Cash Flow	-2,338	-3,133	-1,740	-2,008
Short-Term Debt Issued	-	21	47	-
Long-Term Debt Issued	223	2	7	4
Total Debt Issued	223	23	54	4
Short-Term Debt Repaid	-100	-	-	-204
Long-Term Debt Repaid	-660	-2,498	-753	-48
Total Debt Repaid	-760	-2,498	-753	-252
Net Debt Issued (Repaid)	-537	-2,475	-699	-248
Issuance of Common Stock	264	167	167	255
Repurchase of Common Stock	-1,295	-1,227	-3,795	-2,299
Common Dividends Paid	-3,836	-3,556	-3,309	-3,202
Financing Cash Flow	-5,404	-7,091	-7,636	-5,494
Foreign Exchange Rate Adjustments	-96	-23	-122	-70
Net Cash Flow	720	-2,986	83	2,961
Free Cash Flow	6,351	5,059	7,804	8,648
Free Cash Flow Growth	25.54%	-35.17%	-9.76%	51.08%
Free Cash Flow Margin	15.14%	12.61%	17.88%	20.08%
Free Cash Flow Per Share	3.63	2.89	4.42	4.83
Cash Interest Paid	604	662	563	544
Cash Income Tax Paid	1,723	1,475	1,864	1,941
Levered Free Cash Flow	5,610	4,990	7,340	7,675
Unlevered Free Cash Flow	5,959	5,389	7,689	8,009
Change in Working Capital	-9,217	-2,475	-1,519	-771

Source: S&P Global Market Intelligence. Standard template. Financial Sources.